Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:25:31.451Z.
Calculation as of: 2026-10-06T13:25:31.451Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8f2565128bc52e6b8995a164e764e37a8d90e2a969ed0cbc93651ce94d5a839c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$31.36M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$32.31M
EBITDA Yield
N/A
TTM Avg
0.01%
3Y Avg
0.01%
5Y Avg
0.01%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| aTyr Pharma, Inc. (ATYR) | $28.43M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A | 392.49% | 233.09% | 233.09% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | N/A | 0.01% | 0.01% | 0.01% |
| Kyntra Bio, Inc. (KYNB)vs › | $24.65M | N/A | 1.43% | 1.43% | 1.43% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | N/A | 0.01% | 0.01% | 0.01% |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
